Kathy Boltz, PhD

Most Recent Articles by Kathy Boltz, PhD

Cancer survivors need not be excluded from advanced stage lung cancer trials

A previous history of cancer cancer did not impact clinical outcomes in advanced lung cancer patients and these patients therefore should be considered for inclusion in clinical trials, according to a study .

ASTRO applauds CMS decision to cover annual screening for high-risk lung cancer patients

The American Society for Radiation Oncology (ASTRO) has signaled their approval of the decision by the Centers for Medicare and Medicaid Services to provide coverage for annual lung cancer screening for those at very high risk for lung cancer.

Additional PET/CT scans have value in follow-up of lung cancer patients

Research indicates a high value of scans that could lead to future change of reimbursement policies for follow-up PET/CT studies in lung cancer.

Two major studies strengthen case for prostate cancer drug before chemotherapy

The pioneering prostate cancer drug abiraterone can significantly extend the lives of men with advanced prostate cancer if administered prior to administering chemotherapy, according to phase III clinical trial data.

Study may support active surveillance for favorable intermediate-risk prostate cancer

New research suggests that active surveillance may be an initial approach for men with favorable intermediate-risk prostate cancer.

More Articles by Kathy Boltz, PhD

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs